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Poster Session II S331donor T cells, as measured by absolute counts (p 5 0.0650). More-
over, Nrf2-/- alloreactive T cells in spleen and MLNs expressed less
a4b7 integrin compared to Nrf+/+ T cells (16.9% versus 31.7%, re-
spectively, p 5 0.0079), indicating impaired homing ability of
Nrf2-/- alloreactive T cells.
Together, we conclude that Nrf-2 is an important mediator of al-
loreactive T cells. These data suggest that Nrf-2 could be a novel tar-
get for preventing GVHD while maintaining GVT activity and
improving overall clinical outcomes.494
NHANES III EQUATIONS FOR PFT INTERPRETATION SIGNIFICANTLY AL-
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Bronchiolitis obliterans syndrome (BOS) is a deadly manifestation
of chronic graft-versus-host disease (cGVHD) following HSCT.
The proposed BOS definition includes pulmonary function test
(PFT) parameters of: FEV1\ 75% predicted, FEV1/VC ratio\
0.7, (JAMA 2009) that are determined by reference equations.
NHANES III is the recommended standard, however, older equa-
tions are still used. We sought to determine if the clinical diagnosis
and prognosis of BOS could be predicted by FEV1 and whether the
reference equations influenced these results in a cohort of cGVHD
patients on a NIH protocol. FEV1% predicted and FEV1/FVC for
166 consecutive patients were compared using both NHANES III
and our prior reference equations (Morris/Goldman/Bates-MGB).
The resulting 4 groups were assessed for degree of agreement using
McNemar’s exact test for paired categorical data. Mortality was de-
termined using clinical records and SSDI. Assessing only FEV1%
predicted, 11% (18/166) of patients were classified as normal by
MGB(. 75%), yet abnormal by NHANES III(\75%) while 0/166
were classified as abnormal by MGB(. 75%), yet normal by
NHANES III(\75%) (p\0.0001). Evaluating only FEV1/FVC ra-
tios, 95% (157/166)were concordant by confidence interval.The dis-
cordant ratios were divided evenly between. 0.7 (n5 4) and\0.7 (n
5 5) (p 5 1.00). Using FEV1/VC ratios outside the CI identified 6
more patients who then met criteria for BOS, while 1 was removed
because MGB ratio of\ 0.7 was normal by NHANES III. Using
the amendedBOS definitionwithNHANES III classification, 12 ad-
ditional patients (29%) would have been diagnosed with BOS, and 1
would have been removed from theBOS cohort.NHANES III better
predicted oxygen requirement: 7/8 with FEV1\40% byNHANES
III and 5/8 FEV1\40%byMGB. FEV1 and 2-minute walk velocity
association calculated by either method were weak and comparable
(MGB (r 5 0.25) or NHANES III (r 5 0.24)). For patients with .
1 year of follow-up, 35% of them died (14/40). FEV1\ 35% was
a significant predictor of mortality with either equation (OR 5
20.7, p5 0.001 for NHANES III vs. 18.0, p5 0.01 for MGB equa-
tion).However, theNHANES III equation correctly predicted death
in 9 patients (64%) compared with 6 (42.8%) patients when MGB
equation was used. In conclusion, using NHANES III reference
equationsmarkedly increased the numberof casesmeetingdiagnostic
criteria for BOS and BOS cases categorized using NHANES III
improved prediction of oxygen requirement and survival.495
FEASIBILITY, SAFETY AND EFFICACY OF MARAVIROC, A CCR5 ANTAGO-
NIST, IN GRAFT-VERSUS-HOST DISEASE PREVENTION AFTER REDUCED
INTENSITY CONDITIONED (RIC) ALLOGENEIC STEM CELL TRANSPLANT
(SCT): A PHASE I/II STUDY
Reshef, R., Luger, S.M., Loren, A.W., Frey, N.V., Goldstein, S.C.,
Hexner, E.O., Stadtmauer, E.A., Smith, J., Mick, R., Heitjan, D.F.,
Hoxie, J.A., Emerson, S.G., Vonderheide, R.H., Porter, D.L. University
of Pennsylvania, Philadelphia, PACompelling data implicate the chemokine receptor CCR5 as piv-
otal in the pathogenesis of GvHD through control of lymphocyte
trafficking. We showed that maraviroc (MVC; Selzentry, Pfizer),
a CCR5 antagonist, inhibits in vitro chemotaxis, and hypothesized
that incorporating maraviroc into GvHD prophylaxis will be safe
and limit GvHD without interfering with GvL.
We initiated a phase I/II trial to determine feasibility, safety and
appropriate dose ofMVC, and to determine efficacy when combined
with standard GvHD prophylaxis after RIC SCT. 21 pts received
fludarabine and IV busulfan (6.4 mg/kg) followed by PBSCT from
matched related (6), matched unrelated (12) and 1-antigen mis-
matched unrelated (3) donors. In addition to standard tacrolimus/
methotrexate, MVC at 2 dose levels (150 and 300 mg bid) was given
from day -2 to +30.
The median age was 61 (range 21-74). Indications for SCT were
AML/MDS (10), NHL (4), MF (3), CLL, aplastic anemia, Hodgkin
lymphoma andmyeloma (1 each).MVCwas well tolerated. 3/6 pts at
the 150 mg bid dose level did not reach the targeted Cavg (100 ng/
ml), while the 300 mg bid dose level resulted in adequate Cavg in
6/6 pts and was used as the phase II dose.
The median time to ANC. 500/mLwas 13d (range 10-21) and to
plt . 20k/mL was 13d (range 11-24) with no primary graft failures.
The median whole blood donor chimerism at day 100 was 97%
(range 83-100).
The cumulative incidence of acute GvHD grade II-IV and III-IV
at day 100 is 18% (+/29.8%) and 6% (+/25.9%) respectively in this
high-risk population. Importantly, by day 100 all cases of GvHD
involved only the skin. At a median follow up of 245 days, 4/21 pts
relapsed (2 AML, 1NHL, 1MF) and 7/21 pts died (3 disease-related,
1 GvHD, 1 sepsis, 1 SOS, 1 unrelated).
Biological activity of MVC was assessed in pharmacodynamic as-
says, which test the capacity of patient serum to inhibit CCR5 inter-
nalization and chemotaxis. Patient serum from multiple time points
prevented internalization of CCR5 by RANTES. In vitro chemo-
taxis of normal donor T-cells in response to RANTES was signifi-
cantly impaired following incubation in patient serum from day
0 of transplant (on MVC) as compared to day 60 (off MVC).
Though the phase II portion of the trial is ongoing, we conclude
that MVC 300mg bid was well tolerated and biologically active.
Patients exhibited limited GvHD without excessive relapses or en-
graftment failures. Inhibition of lymphocyte trafficking represents
a promising strategy to reduce acute GvHD.496
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TREATMENT ALLEVIATES ACUTE GRAFT-VERSUS HOST DISEASE AND IM-
PROVES SURVIVAL
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Graft-versus-Host disease (GVHD) causes significant morbid-
ity and mortality after allogeneic transplantation. Acute GVHD
early post transplantation is heralded by a cytokine storm induced
by a dominant T helper type 1(Th1) response, which damages
host tissues like skin, gut, liver and lungs. We hypothesized that
co-transplantation of photochemically (S-59) treated T cells mod-
ulates T cell effecter subsets and their cytokine milieu, and
thereby reduces acute GVHD. To this end, we transplanted
whole bone marrow cells in a major histocompatibility complex
(MHC) antigen mismatched murine model using marrow with
T cells from C57BL/6J/ AKR (acute GVHD model), with
and without S-59 treatment. We observed equivalent elevation
of CD4+Th1 (IL-2 and IFN-g), cytotoxic CD8+ (FAS, IFN-g
and TNF-a) and CD4+Th2 (IL-4, IL-5, IL-6, IL-13) cytokines
in recipients of both groups during the first week after transplan-
tation. While the Th1 cytokines persisted as long as 10 days after
transplantation, there was a shift to a regulatory T cell (Treg) cy-
tokine profile (Transforming growth factor b [TGF-b] and IL-10)
in the group that received the S-59 treated T cells. TGF-b and
IL-10 levels were higher in the peripheral blood and bone mar-
row of the study group compared to controls. This was accompa-
nied by the appearance of FoxP3High CD4+ CD25+ Tregs in the
